Twitter Facebook LinkedIn YouTube

New Listing: Willow Biosciences (CSE:WLLW)

Video Platform Video Management Video Solutions Video Player

By combining with BioCan Technologies and Epimeron, Willow brings together world-leading discovery biologists and business experts in Canada and the United States to advance BioCan’s current biosynthesis platform.

Additional Information:

Company: Willow Biosciences
Website: http:// www.BioCanTechnologies.com
Stock Symbol: CSE:WLLW
Date Published: Apr 15, 2019
Transcript: Available

Video Transcript:

I’m Nadika Vizzy for Investmentpitch Media

Willow Biosciences is one of the latest new listing on the Canadian Securities Exchange, trading under the symbol “WLLW”, having previously traded as Makena Resources, prior to a fundamental change of business.

By combining with BioCan Technologies and Epimeron, Willow brings together world-leading discovery biologists and business experts in Canada and the United States to advance BioCan’s current biosynthesis platform.

BioCan researches and identifies novel genetic factors required for efficient cannabinoid biosynthesis.

The company leverages its expertise in molecular genetics to support cultivar development for Cannabis Sativa, including both cannabis and hemp, and Hop plants, both of which are sources of valuable essential oils.

Much of BioCan's research efforts over the past years has been devoted to the biosynthesis of phytocannabinoids to better understand how they can be produced more efficiently for the pharmaceutical or fine chemical market.

With its corporate office in Calgary, Alberta, it has established research collaborations at the University of British Columbia and has its private laboratory and research facility in Burnaby, BC.

Epimeron, founded in 2014 by a team of researchers from the University of Calgary in Alberta, was spun out to Innovate Calgary, the university’s knowledge transfer and business incubator.

The company discovers, deploys, and optimizes genes that underlie key plant biochemical functions needed for maximum product yield.

For example, Epimeron utilizes yeast fermentation to develop new biosynthetic methods to replace extraction methods of production.

These improved processes can replace older extraction manufacturing methods that relied on isolation of raw materials from harvested crops.

Trevor Peters, President and CEO, stated: “We are very excited to be entering our next phase of development. The capital we have raised will augment and accelerate the work we have already started in developing a biosynthesis platform for producing cannabinoids and will fund us to full scale production”.

The company is well financed, having raised gross proceeds of $29 million from the placement of approximately 828.5 million units priced at $0.035 per unit.

The shares are currently trading at $0.11.

For more information, please visit the company’s websites www.BioCanTechnologies.com and www.epimeron.com, or contact Trevor Peters, President & CEO at 403-669-4848 or email t.peters@BioCanTechnologies.com or Dr. Joseph Tucker, Executive Chairman at 508-627-0485 or email jtucker@epimeron.com.

I’m Nadika Vizzy for Investmentpitch Media